Lung cancer patients with diabetes show prolonged survival

	Tweet

Lung cancer patients with diabetes tend to live longer than patients without diabetes, according to a Norwegian study published in the November issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer.

Researchers did not speculate on the reason for the effect, but said that the survival benefit warranted more study and that diabetes should not be considered a reason to withhold standard cancer treatment.

“Standard therapy should not be withheld from patients with diabetes mellitus provided they are otherwise fit, even if it may be considered a significant comorbidity,” researchers wrote in the study. “The survival benefit may be of clinical importance and should be focused on in future studies.”

Researchers at the Norwegian University of Science and Technology and Trondheim University analyzed 1,677 lung cancer cases from the Nord-Trøndelag Health study (HUNT), the pemetrexed gemcitabine (PEG) study and the Norwegian Lung Cancer Biobank study. It was the first cohort study from a well-defined geographical area, with a stable and large number of inhabitants, investigating lung cancer, diabetes and survival.

They found that the 1-, 2-, and 3-year survival in patients with lung cancer with and without diabetes mellitus were 43% versus 28%, 19% versus 11%, and 3% versus 1%, respectively.

The fact that patients with diabetes mellitus showed a lower frequency of metastatic diseases may partly explain the survival benefit in patients with diabetes mellitus, because the majority of the patients with lung cancer die of metastasis and not of the primary tumor,” researchers wrote. “However, as we adjusted for stage of disease in our analyses this potential advantage can hardly explain the observed increased survival in patients with diabetes mellitus. In addition, increased survival in patients with diabetes mellitus was clearly demonstrated in the PEG study where all patients had advanced lung cancer.”

###

About the Journal of Thoracic Oncology:

The Journal of Thoracic Oncology (JTO) is the official monthly journal of the International Association for the Study of Lung Cancer (IASLC). It is a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer. It emphasizes a multidisciplinary approach, including original research (clinical trials and translational or basic research), reviews and opinion pieces.

To learn more about the JTO please visit http://journals.lww.com/jto/pages/default.aspx.

About the IASLC:
The Denver-based International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1972, the association’s membership includes more than 3,500 lung cancer specialists in 80 countries.

IASLC members promote the study of etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and thoracic malignancies. IASLC disseminates information about lung cancer to scientists, members of the medical community and the public, and uses all available means to eliminate lung cancer as a health threat for the individual patients and throughout the world. Membership is open to any physician, health professional or scientist interested in lung cancer.

###

Renee McGaw

303-724-5796
International Association for the Study of Lung Cancer

RELATED STORIES:
Study reveals cancer-linked epigenetic effects of smoking   Infectious Agent May Impact Lung Cancer   New test predicts if lung cancer will spread   Red Wine May Lower Lung Cancer Risk   Lung Cancer Doesn’t Just Target Smokers   TRUST study data confirms safety and efficacy of erlotinib for advanced lung cancer   New genetic techniques to combat lung cancer   Antibodies may point to early lung cancer   Cigar, pipe smoking may raise lung disease risk, too   Blacks more likely to die of curable lung cancer than whites   Drug fights tumors in advanced lung cancer   Gene Panel Predicts Lung Cancer Survival   Genetic Region Linked to a Five Times Higher Lung Cancer Risk   PET imaging may improve lung cancer diagnosis   Lung cancer slowed by Pfizer drug   Heavy marijuana use not linked to lung cancer   Heaviest Smokers Face Greatest Risk of Death After Lung Cancer Diagnosis   Inhaled drug may prevent lung cancer: study   Counting lung cancer cells helps predict disease   Long-term cannabis use raises risk of lung cancer   Smoking tied to lung cancer in women with HIV   Young women warned of lung cancer risks

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]